TNFSF11 and AL amyloidosis: The introduction of a RANKL-targeting treatment using the monoclonal antibody denosumab (AMG162) has improved clinical outcomes in patients with various skeletal conditions, including osteoporosis, metastatic bone disease, multiple myeloma, and giant cell tumor of bone [16].